Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization

MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization

July 7, 2026Posted inBiotechnology

As MeiraGTx lines up the pieces for a commercial push, the company has new funding to work with.

Post navigation

Previous Post
biomanufacturing-in-space-to-be-key-topic-at-isscr-2026 Biomanufacturing in Space to Be Key Topic at ISSCR 2026
Next Post
A New Development Playbook for PROTACs a-new-development-playbook-for-protacs

Recent Posts

  • Study Maps Hepatitis C Diversity and Drug Resistance Across Viet Nam
  • Why Economic Evidence Matters for Retaining Nurses Across Europe
  • Cardiovascular Health in Minority Groups: From Biology to Social and Discrimination Drivers
  • Few chikungunya cases in Yogyakarta, Indonesia: emerging public health threat or not?
  • Graphical Review of Bibliometric Methods and Applications in Health Sciences

Archives

  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top